Medication info

Empagliflozin and Metformin Hydrochloride Extended-Release Tablet 5/750 mg (Empagliflozin, Metformin Hydrochloride)

Prescription medicationTabletOral
Ingredient · strength
Metformin Hydrochloride with Colloidal Anhydrous Silica›757.5mg / 1 tabletEmpagliflozin›5mg / 1 tablet
Manufacturer / importer
Daewon Pharmaceutical Co., Ltd.
Appearance
Pale pink, oval-shaped extended-release film-coated tablet
Packaging
30 tablets/bottle
Approval status
Active

MFDS item code 202501913 · Approved 2025.07.25

Summary

Main use
Improvement of glycemic control in adults with type 2 diabetes mellitus
Who takes it
Adults
Adult dose
For antidiabetic therapy, the dose of this medicine should be determined based on each patient's current treatment regimen, efficacy, and tolerability, without exceeding the maximum recommended daily doses of each component: empagliflozin 25mg and metformin hydrochloride extended-release 2000mg. To reduce gastrointestinal adverse reactions caused by metformin, take this medicine once daily with the evening meal. Take one tablet of this medicine 10/1000 mg extended-release tablet or 25/1000 mg extended-release tablet once daily. Patients taking this medicine 5/1000 mg extended-release tablet, 12.5/1000 mg extended-release tablet, 5/750mg extended-release tablet, or 12.5/750mg extended-release tablet should take 2 tablets together once daily. To reduce gastrointestinal adverse reactions associated with metformin use, the dose of metformin hydrochloride should be increased gradually. To maintain its extended-release properties, swallow this medicine whole without splitting, crushing, grinding, or chewing. This medicine may not dissolve completely and may be excreted in the feces. It is not known whether the material excreted in the feces contains the active ingredient of the medicine. If a patient repeatedly reports finding this medicine in their feces, healthcare professionals should assess whether blood glucose is being adequately controlled (see Precautions for Use, 5. General precautions). ⦁ For patients who are unable to achieve adequate glycemic control with metformin alone or in combination with other medicines such as insulin, the recommended initial total daily dose when taking this medicine is empagliflozin 10 mg plus the patient's current metformin dose. If empagliflozin 10 mg is well tolerated but additional glycemic control is needed, the dose of empagliflozin may be increased to 25 mg. ⦁ Patients switching from concomitant empagliflozin and metformin therapy to this medicine should receive their previous doses of empagliflozin and metformin. When switching from immediate-release metformin to an extended-release formulation, glycemic control should be closely monitored and the dose appropriately adjusted. Special populations Renal impairment Because dosage adjustment is required according to renal function, assessment of renal function is recommended before starting this medicine and periodically during treatment. No dosage adjustment is necessary in patients with mild renal impairment [creatinine clearance (CrCl) ≧ 60 mL/min or estimated glomerular filtration rate (eGFR) ≧60 mL/min/1.73 m2]. In patients with moderate renal impairment [CKD stage 3A, creatinine clearance (CrCl) ≧ 45 mL/min and <60mL/min or estimated glomerular filtration rate (eGFR) ≧ 45 mL/min/1.73m2 and <60mL/min/1.73m2] who tolerate treatment well and have no other condition that may increase the risk of lactic acidosis, this medicine may be used with adjustment of the metformin hydrochloride dose as follows. - The starting dose of extended-release metformin hydrochloride is 500 mg or 750 mg once daily; therefore, treatment should not be initiated with this medicine. The maximum daily dose of metformin hydrochloride is 1000mg. If creatinine clearance (CrCl) decreases to below 45 ml/min or estimated glomerular filtration rate (eGFR) decreases to below 45 ml/min/1.73m2, discontinue this medicine immediately. Older adults In patients 75 years of age and older, consider renal function and the risk of volume depletion.

Ingredients

Manufacturer
Daewon Pharmaceutical Co., Ltd.

Efficacy & effects

Improvement of glycemic control in adults with type 2 diabetes mellitus

  • Abnormal blood sugar control in adult type 2 diabetes patients
  • cardiovascular disease
  • cardiovascular events
View approved original text

This medication is suitable for adults with type 2 diabetes who have difficulty controlling blood sugar, when used in conjunction with diet and exercise. In particular, it helps improve blood sugar levels by combining empagliflozin and metformin. Furthermore, caution is required for adult type 2 diabetes patients with cardiovascular disease regarding the risk of cardiovascular events. It is important to consult with a healthcare professional before use, and this medication is effectively used for controlling blood sugar and preventing related complications.

How to take

Adult dose

For antidiabetic therapy, the dose of this medicine should be determined based on each patient's current treatment regimen, efficacy, and tolerability, without exceeding the maximum recommended daily doses of each component: empagliflozin 25mg and metformin hydrochloride extended-release 2000mg. To reduce gastrointestinal adverse reactions caused by metformin, take this medicine once daily with the evening meal. Take one tablet of this medicine 10/1000 mg extended-release tablet or 25/1000 mg extended-release tablet once daily. Patients taking this medicine 5/1000 mg extended-release tablet, 12.5/1000 mg extended-release tablet, 5/750mg extended-release tablet, or 12.5/750mg extended-release tablet should take 2 tablets together once daily. To reduce gastrointestinal adverse reactions associated with metformin use, the dose of metformin hydrochloride should be increased gradually. To maintain its extended-release properties, swallow this medicine whole without splitting, crushing, grinding, or chewing. This medicine may not dissolve completely and may be excreted in the feces. It is not known whether the material excreted in the feces contains the active ingredient of the medicine. If a patient repeatedly reports finding this medicine in their feces, healthcare professionals should assess whether blood glucose is being adequately controlled (see Precautions for Use, 5. General precautions). ⦁ For patients who are unable to achieve adequate glycemic control with metformin alone or in combination with other medicines such as insulin, the recommended initial total daily dose when taking this medicine is empagliflozin 10 mg plus the patient's current metformin dose. If empagliflozin 10 mg is well tolerated but additional glycemic control is needed, the dose of empagliflozin may be increased to 25 mg. ⦁ Patients switching from concomitant empagliflozin and metformin therapy to this medicine should receive their previous doses of empagliflozin and metformin. When switching from immediate-release metformin to an extended-release formulation, glycemic control should be closely monitored and the dose appropriately adjusted. Special populations Renal impairment Because dosage adjustment is required according to renal function, assessment of renal function is recommended before starting this medicine and periodically during treatment. No dosage adjustment is necessary in patients with mild renal impairment [creatinine clearance (CrCl) ≧ 60 mL/min or estimated glomerular filtration rate (eGFR) ≧60 mL/min/1.73 m2]. In patients with moderate renal impairment [CKD stage 3A, creatinine clearance (CrCl) ≧ 45 mL/min and <60mL/min or estimated glomerular filtration rate (eGFR) ≧ 45 mL/min/1.73m2 and <60mL/min/1.73m2] who tolerate treatment well and have no other condition that may increase the risk of lactic acidosis, this medicine may be used with adjustment of the metformin hydrochloride dose as follows. - The starting dose of extended-release metformin hydrochloride is 500 mg or 750 mg once daily; therefore, treatment should not be initiated with this medicine. The maximum daily dose of metformin hydrochloride is 1000mg. If creatinine clearance (CrCl) decreases to below 45 ml/min or estimated glomerular filtration rate (eGFR) decreases to below 45 ml/min/1.73m2, discontinue this medicine immediately. Older adults In patients 75 years of age and older, consider renal function and the risk of volume depletion.

Precautions

This medication is used for the treatment of diabetes and contains two components that help control blood sugar. It is essential to verify normal kidney function before taking this medication, and it should not be administered to patients with impaired kidney function. This drug should not be used in patients with serious illnesses such as severe renal impairment, acute heart failure, acute myocardial infarction, or severe infections. Additionally, individuals allergic to any components of this medication should not take it. This medication can cause a rare but very serious side effect known as lactic acidosis, so special caution is required in cases of dehydration, hypoxia, or liver dysfunction. When used in combination with other diabetes medications, hypoglycemia may occur, so dosage adjustments may be necessary when used together with insulin or sulfonylureas. This drug may increase the risk of genital and urinary tract infections, so consult a doctor immediately if any infection symptoms occur. Regular blood tests are important to monitor kidney function and vitamin B12 levels during treatment. It is advisable for pregnant women, women of childbearing potential, or nursing mothers to avoid using this medication. Elderly patients or those at risk of fluid loss should be cautious about dehydration and low blood pressure and may need to temporarily discontinue the drug if necessary. Patients scheduled for surgery should stop taking this medication 48 hours prior to surgery and resume only after confirming normal kidney function post-surgery. This drug should be swallowed whole and not chewed or crushed, and its coating may appear in stools, which is normal. Overdose can cause severe side effects like lactic acidosis, so immediate medical attention is required for any unusual symptoms. It is advisable to avoid excessive alcohol consumption while taking this medication, and any changes in symptoms or adverse reactions should be reported to a healthcare professional immediately.

Side effects

  • Hypoglycemia
  • urinary tract infection
  • genital infection
  • increased urination
  • decreased and deficiency of vitamin B12
  • ketoacidosis
  • lactic acidosis
  • decreased fluid volume
  • nausea
  • vomiting
Show 147 more
  • diarrhea
  • abdominal pain
  • loss of appetite
  • constipation
  • abnormal liver function tests
  • hepatitis
  • dysgeusia
  • pruritus
  • rash
  • urticaria
  • erythema
  • angioedema
  • difficulty urinating
  • interstitial nephritis
  • thirst
  • elevated serum lipids
  • increased serum creatinine
  • decreased glomerular filtration rate
  • increased hematocrit
  • perineal necrosis
  • liver damage
  • urosepsis
  • pyelonephritis
  • rash
  • urticaria
  • angioedema
  • perineal necrosis
  • chronic gastritis
  • various neurological disorders
  • cerebral infarction
  • soft tissue infection
  • pneumonia
  • ankle fracture
  • epicondylitis
  • facial bone fracture
  • musculoskeletal pain
  • myocardial infarction
  • pancreatic adenocarcinoma
  • diarrhea
  • nausea
  • gastric ulcer
  • colitis
  • vomiting
  • ischemic colitis
  • gastrointestinal bleeding
  • appendiceal abscess
  • appendicitis
  • chronic otitis media
  • peritonsillar abscess
  • pulmonary tuberculosis
  • acute pyelonephritis
  • sepsis
  • subcutaneous abscess
  • adnexal-ovarian abscess
  • vestibular neuritis
  • headache
  • cerebral infarction
  • intracranial aneurysm
  • fever
  • vascular stent stenosis
  • vascular stent thrombosis
  • elevated alanine aminotransferase
  • elevated aspartate aminotransferase
  • ureteral stones
  • acute kidney injury
  • cervicitis
  • hyperglycemia
  • hyponatremia
  • insomnia
  • dizziness
  • vulvar pruritus
  • genital pruritus
  • dyslipidemia
  • hyperglycemia
  • dermoid cyst
  • seborrheic dermatitis
  • atopic dermatitis
  • diabetic foot
  • nummular eczema
  • heat rash
  • sebaceous gland hyperplasia
  • lumbar spinal stenosis
  • myalgia
  • limb pain
  • musculoskeletal chest pain
  • arthralgia
  • cervical stenosis
  • fibromyalgia
  • flank pain
  • fracture pain
  • muscle weakness
  • osteoarthritis
  • osteoporosis
  • rotator cuff syndrome
  • astigmatism
  • cataract
  • allergic conjunctivitis
  • blurred vision
  • corneal erosion
  • glaucoma
  • macular fibrosis
  • ocular discomfort
  • conjunctival congestion
  • pathologic myopia
  • retinal detachment
  • retinal crystal formation
  • retinal vein occlusion
  • retinal detachment with tears
  • eyelid swelling
  • visual impairment
  • vitreous floaters
  • vitreous hemorrhage
  • epistaxis
  • asthma
  • exertional dyspnea
  • wet cough
  • allergic rhinitis
  • residual phlegm
  • cough
  • epistaxis
  • allergic rhinitis
  • skin laceration
  • rib fracture
  • long ligament syndrome
  • angina
  • palpitations
  • Prinzmetal angina
  • coronary artery disease
  • tachycardia
  • arteriosclerosis
  • deep vein thrombosis
  • diabetic vascular complications
  • peripheral arterial occlusive disease
  • anxiety
  • depression
  • sleep disorders
  • acute cholecystitis
  • autoimmune hepatitis
  • cholelithiasis
  • hepatitis
  • otalgia
  • postural dizziness
  • dizziness
  • anemia
  • lymphadenopathy
  • hypothyroidism
  • thyroid nodule

Not everyone experiences these, and they can vary from person to person.

Storage

This medication should be stored in a tightly sealed container, protected from air and moisture, and maintained at room temperature between 1 to 30 degrees Celsius. Proper storage will safely preserve the medication's effectiveness.

Appearance and packaging

Appearance

Pale pink, oval-shaped extended-release film-coated tablet

Package unit

30 tablets/bottle

Same-ingredient medicines

Even with the same ingredient, strength, dosage form and how it is taken can differ.

Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.

Questions about this medicine

No questions yet.

For anything that needs medical judgment, consult a doctor or pharmacist.

Related searches

Search tags

Suggested searches

This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.